NIPRUSS 60 mg

DRUG2 trials

Sponsors

University Hospital Maastricht, Amsterdam UMC

Conditions

Heart failure with preserved ejection fractionUnequivocal epicardial and/or microvascular vasospastic angina

Phase 2

Vericiguat in Vasospastic Angina (ViVA)

RecruitingCTIS2022-502998-42-00

Amsterdam UMCUnequivocal epicardial and/or microvascular vasospastic angina

Start: 2025-02-10Target: 55Updated: 2026-01-21

Phase 4

The effect of empagliflozin on peripheral microvascular dysfunction in heart failure with preserved ejection fraction

CompletedCTIS2022-501682-45-00

University Hospital MaastrichtHeart failure with preserved ejection fraction

Start: 2023-02-13End: 2024-12-01Target: 48Updated: 2022-12-01